Do you utilize Mammaprint testing to determine whether or not to offer neoadjuvant chemotherapy for high risk ER+ breast cancer?  


Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist at Warren Alpert Medical School of Brown University
I agree that in high-risk patients (clinical T4, N...
Medical Oncologist at UH Samaritan Medical Center
@William M. Sikov if it ends up a high risk (T2N1,...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution